| ²é¿´: 5279 | »Ø¸´: 20 | ||
| ±¾Ìû²úÉú 2 ¸ö DRDEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
isaballa00ͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
ÔÁÏÒ©Ó븨ÁÏÏàÈÝÐÔʵÑé
|
|
ÏÖÔÚ×öһƬ¼Á£¬¸ù¾ÝCTDÒªÇó£¬ÒªÌṩ¸¨ÁÏÏàÈÝÐÔʵÑ飬Çë½Ì´ó¼Ò¾ßÌåÊÇÔõô²Ù×÷£¿ |
» ²ÂÄãϲ»¶
ϸ°ûËÀÍöз½Ê½£ºÍËÀÍö
ÒѾÓÐ9È˻ظ´
ÎåÒØ´óѧҩѧÓëʳƷ¹¤³ÌѧԺÕÐÊÕµ÷¼ÁÉúÎïÓëҽҩר˶
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ108È˻ظ´
ŧ¶¾Ö¢£¨Ã¤³¦½áÔú£©
ÒѾÓÐ22È˻ظ´
ÈçºÎÀí½âhopf map
ÒѾÓÐ0È˻ظ´
ÌáÈ¡Ö×Áö×éÖ¯Ïû»¯ºóµÃµ½µÄÖ×Áöϸ°ûËÀÍöÂʹý¸ß
ÒѾÓÐ0È˻ظ´
WoSÒ»ÇøFrontiers in Genome Editing»ùÒò±à¼·½·¨ÓëÓ¦Ó÷½ÏòרÌâÑû¸å£¨Ó°ÏìÒò×Ó4.9£©
ÒѾÓÐ0È˻ظ´
WoSÒ»ÇøFrontiers in Genome Editing»ùÒò±à¼·½·¨ÓëÓ¦Ó÷½ÏòרÌâÑû¸å£¨Ó°ÏìÒò×Ó4.9£©
ÒѾÓÐ0È˻ظ´
WoSÒ»ÇøFrontiers in Genome Editing»ùÒò±à¼·½·¨ÓëÓ¦Ó÷½ÏòרÌâÑû¸å£¨Ó°ÏìÒò×Ó4.9£©
ÒѾÓÐ0È˻ظ´
WoSÒ»ÇøFrontiers in Genome Editing»ùÒò±à¼·½·¨ÓëÓ¦Ó÷½ÏòרÌâÑû¸å£¨Ó°ÏìÒò×Ó4.9£©
ÒѾÓÐ0È˻ظ´
¹òÇóÒ»Ö§AAV293ϸ°û
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
×¢Éä¼ÁÒ©Æ·Óë°ü×°²ÄÁÏÏàÈÝÐÔʵÑé²ÄÁÏ 2011.7 ÉϺ£
ÒѾÓÐ48È˻ظ´
ÈܳöÇúÏßÎÊÌâ
ÒѾÓÐ15È˻ظ´
Çó½âÉúÎïÏàÈÝÐÔʵÑ飿£¿£¿£¿£¿£¿£¿£¿£¿
ÒѾÓÐ12È˻ظ´
Ô¸¨ÁÏÏàÈÝÐÔ ¹úÄÚÍâÖ¸µ¼ÔÔòÇóÖú
ÒѾÓÐ9È˻ظ´
Ô¸¨ÁÏÏàÈÝÐÔÊÔÑé-0Ìì±È½Ï
ÒѾÓÐ4È˻ظ´
·ÂÖÆÒ©´¦·½Ñо¿»ù±¾¸ÅÂÔ
ÒѾÓÐ26È˻ظ´
Ô¸¨ÁÏÏàÈÝÐÔµÄ×ÊÁϵ½ÄĶùÕÒ°¡£¿
ÒѾÓÐ6È˻ظ´
Ò©Î︨ÁÏÏàÈÝÐÔÑо¿ÖеÄÔÓÖÊÎÊÌâ
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú¡¿¸¨ÁÏÏàÈÝÐÔÊÔÑé
ÒѾÓÐ15È˻ظ´
¡¾ÇóÖú¡¿ÔÁÏÒ©ËáÆÆ»µºÍ¼îÆÆ»µÊµÑéµÄÁ½¸ö¸öÎÊÌâ
ÒѾÓÐ32È˻ظ´
¡¾ÇóÖú¡¿ÐÂÒ©ÔÁÏÒ©µÄÈܽâ¶ÈʵÑé
ÒѾÓÐ12È˻ظ´
ÔÁÏÒ©ÖÆ½ºÄÒʱÎüʪÐԴ󣬸ÃÈçºÎ½â¾ö£¿¼Óʲô¸¨ÁÏ¿ÉÒÔ½â¾öÎÊÌ⣿
ÒѾÓÐ4È˻ظ´

peggywu
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 47
- Ìû×Ó: 10
- ÔÚÏß: 10.3Сʱ
- ³æºÅ: 1607727
- ×¢²á: 2012-02-09
- רҵ: Ò©ÀíѧÆäËû¿ÆÑ§ÎÊÌâ
9Â¥2012-02-13 10:12:53
missjane
ľ³æ (ÖøÃûдÊÖ)
- DRDEPI: 1
- Ó¦Öú: 22 (СѧÉú)
- ½ð±Ò: 9422.1
- É¢½ð: 553
- ºì»¨: 4
- Ìû×Ó: 1432
- ÔÚÏß: 108.8Сʱ
- ³æºÅ: 531971
- ×¢²á: 2008-03-24
- ÐÔ±ð: MM
- רҵ: Ò©Îïѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
zhychen2008(½ð±Ò+1, DRDEPI+1): ¸Ðл»ØÌû½»Á÷ 2011-08-04 16:57:44
isaballa00(½ð±Ò+1): 2011-08-08 15:08:42
zhychen2008(½ð±Ò+1, DRDEPI+1): ¸Ðл»ØÌû½»Á÷ 2011-08-04 16:57:44
isaballa00(½ð±Ò+1): 2011-08-08 15:08:42
| Ö÷Ò©Ó븨ÁÏÏàÈÝÐÔÑо¿ÊÇ´¦·½Ç°Ñо¿¹¤×÷ÖеÄÒ»ÏîÖØÒªÄÚÈÝ¡£ÏàÈÝÐÔÑо¿µÄ¾ßÌåÊÔÑé·½·¨Ó¦¸ù¾ÝÖÆ¼ÁÆ·ÖֵľßÌåÇé¿öÈ·¶¨¡£ÀýÈç¶ÔÓÚ¿Ú·þ¹ÌÌåÖÆ¼Á£¬¿ÉÑ¡Èô¸ÉÖÖ¸¨ÁÏ£¬È縨ÁÏÓÃÁ¿½Ï´óµÄ£¨ÈçÌî³ä¼ÁµÈ£©£¬¿ÉÓÃÖ÷Ò©£º¸¨ÁÏ£½1£º5µÄ±ÈÀý»ìºÏ£¬ÈôÓÃÁ¿½ÏСµÄ£¨ÈçÈ󻬼ÁµÈ£©£¬ÔòÓÃÖ÷Ò©£º¸¨ÁÏ£½20£º1µÄ±ÈÀý»ìºÏ£¬È¡Ò»¶¨Á¿£¬°´Îȶ¨ÐÔÓ°ÏìÒòËØÊÔÑé·½·¨£¬·Ö±ðÔÚÇ¿¹â£¨4500¡À500Lux£©¡¢¸ßΣ¨60¡æ£©¡¢¸ßʪ£¨Ïà¶Ôʪ¶È90¡À5%£©µÄÌõ¼þÏ·ÅÖÃ10Ì죬ÓÃHPLC»òÆäËûÊÊÒ˵ķ½·¨¼ì²éº¬Á¿¼°ÓйØÎïÖÊ·ÅÖÃǰºóÓÐÎޱ仯£¬Í¬Ê±¹Û²ìÍâ¹Û¡¢É«ÔóµÈÒ©ÎïÐÔ×´µÄ±ä»¯¡£±ØÒªÊ±£¬¿ÉÓÃÔÁÏÒ©ºÍ¸¨ÁÏ·Ö±ð×öƽÐжÔÕÕʵÑ飬ÒÔÅбðÊÇÔÁÏÒ©±¾ÉíµÄ±ä»¯»¹ÊǸ¨ÁϵÄÓ°Ïì¡£ |

2Â¥2011-08-04 13:03:51
dongliang09
½ð³æ (СÓÐÃûÆø)
- DRDEPI: 1
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 1458.6
- Ìû×Ó: 81
- ÔÚÏß: 23.1Сʱ
- ³æºÅ: 936526
- ×¢²á: 2010-01-04
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï
zhychen2008(½ð±Ò+2): ¸Ðл»ØÌû½»Á÷ 2011-08-04 17:01:07
zhychen2008(½ð±Ò+2): ¸Ðл»ØÌû½»Á÷ 2011-08-04 17:01:07
|
ÒÔÏÂÊDzμÓANDAÅàѵʱµÄ×ÊÁÏ£¨Ã»·Ò룩£¬½ö¹©²Î¿¼¡£ Excipient Compatibility¸¨ÁÏÏàÈÝÐÔÑо¿ Expectation in Pharmaceutical Development from regulatory bodies: •To understand with which common excipients the drug is compatible; •To give a ranking order of the compatibility in each category ofexcipients; •To lay foundation of formulation design for a compound In generic world, excipients used in the product are known and the product is stable. But, API-compatibility study is still needed because source of excipients is different. Different source of an excipient may have different starting materials, different process, and different impurity profile, thus indicating a potential impact on API ¸¨ÁÏÏàÈÝÐÔÑо¿µÄʵÑéÉè¼Æ(1) •Select excipients: >2 excipients in each category (e.g., filler, binder, disintergant, glidant, wetting agent, lubricant, coating materials); •Ratio of API to excipient: similar to the common ratio in a formulation; API:Filler: 1:10 API: Binder or disintegrant: 1:1 API: lubricant or glidant, or surfactant: 10:1 •Container/closure: scintillation vial/tight seal. 500 mg powders/vial. •Storage conditions: Stressed! 40¡ãC/75% RH open/closed, 55-60¡ãC ambient humidity. •Sampling time: Initial, 2 weeks, 4 weeks. •Sample analysis: physical appearance and impurity Other things to be considered: 1: API control must be prepared and tested in order to know the real compatibility problem under stressed conditions. 2: A second set of samples may be prepared in which 5% of water is added into the powder mixture. Double the work load☺ 3:Stearicacid and Dicalciumphosphate at 40¡ã ¸¨ÁÏÏàÈÝÐÔÑо¿½á¹ûµÄ·ÖÎö •To obtain possible quantitative relationships to excipient characteristics and interaction rates •Physical change: caking, liquefaction, and odor or gas formation, discoloration (amines, sugars) •Impurities: total level and individual level existing peaks vsnew peaks. •To give the ranking order: selection of ¡°relatively¡±good one over ¡°less¡±good in the formulation |
4Â¥2011-08-04 14:30:07
rnyter960
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 8 (Ó×¶ùÔ°)
- ½ð±Ò: 3430.1
- É¢½ð: 100
- ºì»¨: 1
- Ìû×Ó: 119
- ÔÚÏß: 41.7Сʱ
- ³æºÅ: 320793
- ×¢²á: 2007-03-10
- ÐÔ±ð: MM
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
zhychen2008(½ð±Ò+1): ¶àл»ØÌû½»Á÷ 2011-08-04 17:01:14
zhychen2008(½ð±Ò+1): ¶àл»ØÌû½»Á÷ 2011-08-04 17:01:14
| ÖÆ¼Á°Ù¿ÆÈ«ÊéµÚ¶þ¾íƬ¼ÁÖÐÓÐÌáµ½£¬¿ÉÒÔ¿´¿´´ËÊé |
5Â¥2011-08-04 14:38:55









»Ø¸´´ËÂ¥